EP3441097A1 - Nebulizer for aerosolizing a liquid with a detachable cover including a valve system - Google Patents
Nebulizer for aerosolizing a liquid with a detachable cover including a valve system Download PDFInfo
- Publication number
- EP3441097A1 EP3441097A1 EP17185224.7A EP17185224A EP3441097A1 EP 3441097 A1 EP3441097 A1 EP 3441097A1 EP 17185224 A EP17185224 A EP 17185224A EP 3441097 A1 EP3441097 A1 EP 3441097A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nebulizer
- inner conduit
- cover
- aerosol
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006199 nebulizer Substances 0.000 title claims abstract description 99
- 239000007788 liquid Substances 0.000 title claims abstract description 47
- 238000002663 nebulization Methods 0.000 claims abstract description 32
- 239000000443 aerosol Substances 0.000 claims abstract description 18
- 230000000241 respiratory effect Effects 0.000 claims description 30
- 230000001815 facial effect Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000003595 mist Substances 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 20
- 239000007789 gas Substances 0.000 description 26
- 239000003570 air Substances 0.000 description 17
- 230000002093 peripheral effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012080 ambient air Substances 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940012982 picot Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
- A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
Definitions
- the present invention concerns a valve system arranged on the detachable cover of a nebulizer useable in aerosoltherapy.
- Nebulizing devices are devices useable for delivering an inhalation therapy, i.e. an aerosoltherapy, to a patient in need thereof.
- Nebulizers are used in combination with a source of gas, typically compressed air, for nebulizing a drug solution thereby obtaining a mist containing droplets having suitable sizes allowing them reaching the lower airways of the patient that has to inhale said mist in the course of his/her aerosoltherapy.
- a source of gas typically compressed air
- nebulizers are not suitable because they generally comprise a permanent opening for venting the CO 2 -containing gases exhaled by the patient during the expiration phases.
- the main drawback of such a permanent opening is that the drug-containing mist can also escape through said opening, thereby wasting a significant amount of drug in the environment, i.e. in the surrounding atmosphere.
- a goal of the present invention is to propose an improved nebulizer that limits the waste of drug in the surrounding atmosphere.
- a solution according to the present invention is a nebulizer for aerosolizing a liquid, in particular a liquid drug, comprising :
- a nebulizer according to the present invention can comprise one or several of the following additional features:
- FIG. 1 A preferred embodiment of a nebulizer according to the present invention is shown in the enclosed Figures, among which:
- Figure 1 represents an exploded view an embodiment of a nebulizer 1 according to the present invention designed for aerosolizing a liquid, such as a drug useable in aerosoltherapy, which comprises:
- the reservoir 3 comprises a liquid tank 14, also called liquid vessel or compartment, for receiving the liquid to be aerosolized, and further an inner conduit 18, as shown in Fig. 3 , arranged so as to project axially and upwardly into the liquid tank 14 of the reservoir 3.
- the tank 14 of the reservoir 3 has a "cup-like" shape.
- the inner conduit 18 is arranged at the center of the liquid tank 14 of the reservoir 3.
- the role of the inner conduit 18 is to convey a pressurized gas delivered by a gas source (not shown), such as compressed air, fluidly connected to the upstream end 18a of the inner conduit 18.
- a gas source such as compressed air
- the gas flow travels into the lumen or inner passage 18c of the inner conduit 18 and is delivered by the downstream end 18b of the inner conduit 18 for creating the mist or aerosol as explained below.
- the reservoir 3 is detachably attached to the nebulizer body 2, for instance they are snap-fitted or threadedly-coupled together, or similarly adapted for repeated attachment/detachment.
- the nebulizer body 2 forming the main part of the nebulizer 1 comprises a top opening 10 that is closed by an upper cover 7 forming the "top” or “roof” of the nebulizer body 2 as shown in Figure 1 .
- the nebulizer body 2 comprises, as shown in Figure 3 :
- At least a part of the nebulization chamber 5 is positioned between the peripheral wall 2a of the nebulizer body 2 and the axially-arranged inner conduit 13, and further located above the liquid tank 14.
- the lower end 13b of the axially-arranged inner conduit 13 of the nebulizer body 2 forms a sleeve around the downstream end 18b of the inner conduit 18 of the reservoir 3.
- the lower end 13b of the axially-arranged inner conduit 13 of the nebulizer body 2 further projects into the liquid tank 14 of the reservoir 3 and terminates close to the bottom 14a of the liquid tank 14 as shown in Figure 3 , preferably at a distance of less than about 2 mm.
- a spacing 22 is kept, on the one hand, between the extremity of the lower end 13b of the axially-arranged inner conduit 13 and the bottom 14a of the liquid tank 14 and, on the second hand, between the inner wall of the lower end 13b of the axially-arranged inner conduit 13 and the outer wall of the downstream end 18b of the inner conduit 18 of the reservoir 3.
- the distance between the inner wall of the lower end 13b of the axially-arranged inner conduit 13 and the outer wall of the downstream end 18b of the inner conduit 18 of the reservoir 3 is of less than about 1 mm.
- the liquid contained into the tank 14 of the reservoir 3 should be able to circulate in said spacing 22 for reaching the aerosol-generating system 4, 23,24, as explained below.
- the aerosol-generating system 4, 23, 24 is arranged in the lumen 13c of the inner conduit 13 of the nebulizer body 2 and comprises, as shown in Figure 3 :
- Such an aerosol-generating system 4, 23, 24 can generate the aerosol mist thanks to a Venturi effect.
- This principle is well-known in the art.
- pressurized air is conveyed and delivered by by the inner conduit 18 of the reservoir 3, at a high speed and a constant flowrate.
- the liquid solution travels in the spacing 22, i.e. it is upwardly pulled by the suction effect, and is then delivered by the small orifice 24 of the nozzle element 23 toward the deflector element 4.
- a mist of liquid droplets is created by the impact of the liquid on the deflector element 4.
- the smaller droplets create the desired aerosol mist that is recovered into the nebulization chamber 5, whereas the larger and/or heavier droplets return to the liquid tank 14.
- the aerosol mist can thereafter be inhaled by the patient via a respiratory interface 6.
- a respiratory interface 6 also called “patient interface”
- patient interface is fixed to the nebulizer body 2 and is in fluid communication with the nebulization chamber 5 so that the aerosol created in the nebulization chamber 5 can be delivered to a patient by said respiratory interface 6 as illustrated in Figure 3 .
- the respiratory interface 6 can be a mouthpiece 30, or a mouth or facial respiratory mask 31, 32, or similar.
- the choice of the most suitable interface 6 depends on the type of medication to be taken and on the type of patients i.e. the facial mask is suitable for non collaborative pediatric patients, while the mouthpiece and mouth mask are better for adults.
- the respiratory interface 6 is a mouthpiece 30 with an inner passage 15, that is designed so that the patient takes it into his/her mouth for inhaling the drug-containing mist.
- the mouthpiece 30 is traversed by an inner passage 15 that is in fluid communication with the nebulization chamber 5.
- the respiratory interface 6 comprises a proximal end 6a connected to the nebulizer body 2 and a distal end 6b that is free and which comprises the exit orifice 16 of the inner passage 15.
- the distal end 6b is further designed so as to form a "beak-shape nozzle" that the patient takes in mouth, whereas in the case of a mouth or facial respiratory mask 31, 32, the distal end 6b is further designed so as to form an enclosure that is large enough for receiving at least a part of the patient's nose or nose and mouth, through the exit orifice 16.
- Figures 7a-7b show the attachment of a mouthpiece 30 to the nebulizer body 2 of the nebulizer 1 of Figure 1 .
- attaching of a mouth or facial respiratory mask 31, 32 can be operated similarly.
- the nebulizer 1 further comprises a detachable cover 7 that forms the "top" of the nebulizer 1 as forming the ceiling of the nebulizer body 2 as illustrated in Figures 1 , 2 and 3 .
- the cover 7 comprises a lower peripheral border 11 cooperating with an upper peripheral border 12 delimiting the top opening 10 of the nebulizer body 2.
- the cover 7 can, for instance, be snap-fitted or similar to the nebulizer body 2 so that the lower peripheral border 11 of the cover 7 cooperates with the upper peripheral border 12 of the top opening 10 of the nebulizer body 2.
- connecting structures 25, 26, such as pin(s), finger(s), claw(s), clamp(s) 25 or the like and corresponding lodging(s) 26, groove(s) or the like, are arranged on the cover 7 and/or the nebulizer body 2 and cooperate together for allowing a tight and integral fixing of the cover 7 to the nebulizer body 2.
- the top cover 7 further comprises a grip portion 17 arranged in its outer wall that allows the user, e.g. the patient, to easily remove the cover 7 when attached to the nebulizer body 2, for instance for cleaning the nebulization chamber 5.
- the grip portion 17 can comprise a textured area, i.e. a not-smooth surface, allowing a good grip to the user, e.g. a textured area comprising "ridges" and "valleys".
- similar grip portions 27 are also arranged in the peripheral wall 2a of the nebulizer body 2 for improving the hand grip of the nebulizer 1 by the patient.
- All the components of the nebulizer 1, i.e. cover 7, nebulizer body 2..., are preferably made of plastic material(s), such as PP, PC, ABS, PA, PSU or similar materials, while the masks are made of a soft elastomeric material, such as silicone or the like.
- the cover 7 comprises a valve system 8, 9 comprising a pair of valves, i.e.
- the one-way expiration valve 9 is located between the one-way inspiration valve 8 and the respiratory interface 6, when the cover 7 is integrally fixed to the nebulizer body 2.
- the inspiration valve 8 is located on the cover 7 facing and in fluid communication with the air inlet located at the upper end 13a of the axially-arranged inner conduit 13, and opens only during inspiration phases of the patient by action of the negative pressure generated by the patient's inspiration, i.e. during inspiration phases.
- the inspiration valve 8 provides an additional flow of ambient air that enters into the nebulization chamber 5 thereby boosting the nebulization (due to a "double" Venturi effect) and significantly increasing the amount of aerosol mist formed into said nebulizing chamber 5, and further thereby increasing the nebulization rate of the liquid drug, i.e. the solution containing the medication.
- the on-way inspiration valve 8 allows air to only travel from the outside to the inside of the nebulizer 1, i.e. to enter into the nebulization chamber 5 via the axially-arranged inner conduit 13.
- the expiration valve 9 is located next to the inspiration valve 8 on the detachable cover 7, but closer to the mouthpiece 6 than the inspiration valve 8.
- Said expiration valve 9 opens by action of the CO 2 -containing gases exhaled by the patient that create an overpressure (i.e. pressure > 1 bar) in the respiratory interface 6 and at the inlet of the nebulization chamber 5, while the patient is exhaling gases.
- Said overpressure allows gases to be vented from the nebulizer 1, through the expiration valve 9, when the patient exhales into the respiratory interface 6.
- the on-way expiration valve 9 allows said CO 2 -containing gas to only travel from the inside to the outside of the nebulizer 1, i.e. to be vented to the atmosphere.
- the patient does not remove the respiratory interface 6, such as the mouthpiece 30 out of his/her mouth, before starting to expire CO 2 -containing gases.
- the patient can execute his/her aerosoltherapy by both inhaling and exhaling gases through the respiratory interface 6 and the cover 7 (see arrows in Fig. 2 ), the amount of aerosolized drug wasted in the environment is considerably reduced, compared with prior art nebulizers, as the exit of expired gases is controlled by the one-way expiration valve 9, i.e. there is no permanent opening for exhaled air.
- valves 8, 9 on the detachable cover 7, rather than on the respiratory interface 6 because it reduces the number of expiration valves that otherwise would have been necessary for using the nebulizer 1 with different kinds of respiratory interfaces 6, i.e. mouthpiece 30, mouth and facial masks 31, 32, each equipped with an expiration valve.
- the nebulizer 1 of the present invention is usable in combination with a source of gas, such as compressed air, for nebulizing a drug-containing solution and thereby obtaining a mist containing droplets of medication having suitable sizes so as to be able to reach the lower airways of the patient that has to inhale said mist in the frame of his/her aerosoltherapy.
- a source of gas such as compressed air
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nozzles (AREA)
Abstract
Description
- The present invention concerns a valve system arranged on the detachable cover of a nebulizer useable in aerosoltherapy.
- Nebulizing devices, commonly called nebulizers, are devices useable for delivering an inhalation therapy, i.e. an aerosoltherapy, to a patient in need thereof.
- Nebulizers are used in combination with a source of gas, typically compressed air, for nebulizing a drug solution thereby obtaining a mist containing droplets having suitable sizes allowing them reaching the lower airways of the patient that has to inhale said mist in the course of his/her aerosoltherapy.
- So far, different architectures of nebulizers have been proposed.
- However, most of the current nebulizers are not suitable because they generally comprise a permanent opening for venting the CO2-containing gases exhaled by the patient during the expiration phases.
- The main drawback of such a permanent opening is that the drug-containing mist can also escape through said opening, thereby wasting a significant amount of drug in the environment, i.e. in the surrounding atmosphere.
- A goal of the present invention is to propose an improved nebulizer that limits the waste of drug in the surrounding atmosphere.
- A solution according to the present invention is a nebulizer for aerosolizing a liquid, in particular a liquid drug, comprising :
- a reservoir for receiving a liquid to be aerosolized,
- a nebulizer body comprising an aerosol-generating system for generating an aerosol and a nebulization chamber for containing the aerosol,
- a cover forming the top of the nebulizer,
- a one-way inspiration valve allowing air entering into the nebulization chamber
- and a one-way expiration valve allowing gas exiting the nebulization chamber, especially CO2-containing gas, during the expiration phases of the patient.
- In relation to the present invention :
- an "aerosol" is a mist containing droplets of liquid, for instance a liquid drug, and a gas, such as air,
- a "gas" is formed of a unique compound (i.e. a pure gas) or of several compounds (i.e. gas mixture) that is/are in gaseous form.
- a "liquid drug" or a "drug-containing solution" is a solution that comprises one or several liquid compounds and optionally one or several solid compounds dissolved, suspended or similarly incorporated in said one or several liquid compounds.
- Depending on the embodiment, a nebulizer according to the present invention can comprise one or several of the following additional features:
- the one-way inspiration valve is configured for allowing gas, such as ambient air, to enter into the nebulization chamber of the nebulization body, during the inspiration phases of the patient, but for preventing any exit/escape of gas through said one-way inspiration valve during the expiration phases of the patient.
- the one-way expiration valve is configured for allowing gas, especially CO2-containing gas, exiting the nebulization chamber during the expiration phases of the patient, but for preventing any entry of gas through said one-way expiration valve during the inspiration phases of the patient.
- the nebulizer further comprises a respiratory interface in fluid communication with the nebulization chamber.
- the respiratory interface comprises a mouthpiece, a mouth mask or a facial mask.
- the one-way expiration valve is located between the one-way inspiration valve and the respiratory interface, when the cover is integrally fixed to the nebulizer body.
- the reservoir comprises a liquid tank for receiving a liquid to be aerosolized.
- the liquid tank has a cup-like shape.
- the aerosol-generating system comprises a nozzle element comprising an orifice and a deflector element facing the orifice of the nozzle element.
- the aerosol-generating system comprises a nozzle element for accelerating the air delivered by a source of compressed air, thereby creating a Venturi or suction effect pulling some liquid solution out of the liquid tank.
- the aerosol-generating system comprises deflector element for atomizing the liquid thereby creating a mist containing liquid droplets.
- the nebulizer body further comprises an axially-arranged inner conduit comprising a lower end projecting into the liquid tank of the reservoir.
- the lower end of the inner conduit terminates close to the bottom of the liquid tank.
- the reservoir further comprises an inner conduit projecting axially and upwardly into the liquid tank.
- the axially-arranged inner conduit of the nebulizer body is arranged as a sleeve around a downstream end of the inner conduit of the reservoir.
- the axially-arranged inner conduit of the nebulizer body is spaced from the downstream end of the inner conduit of the reservoir by a spacing.
- the nozzle element and the deflector element of the aerosol-generating system are arranged into the lumen of the inner conduit of the nebulizer body.
- the inspiration valve of the cover is facing and in fluid communication with the air inlet located at the upper end of the axially-arranged inner conduit.
- the nebulization chamber is located above the liquid tank.
- the cover comprises a grip portion.
- the cover is detachably fixed to the nebulizer body.
- the cover is press-fitted, snap-fitted or similarly detachably affixable to the nebulizer body.
- the cover comprises a grip portion, such as a textured area, preferably arranged on its outer wall, that allows the user to easily decouple the cover from the nebulizer body.
- the one-way expiration valve is located between the one-way inspiration valve and the respiratory interface, when the cover is integrally fixed to the nebulizer body.
- the respiratory interface comprises a mouthpiece, a mouth mask or a facial mask.
- the nebulizer body, the reservoir and/or the cover are made of polymer, such as PP, PC, ABS, PA, PSU or any other suitable plastic material.
- the respiratory interface comprises an inner passage.
- the inner passage of the respiratory interface is in fluid communication with the nebulization chamber.
- the respiratory interface comprises a proximal end connected to the nebulizer body and a distal end that is free.
- the distal end of the respiratory interface comprises the exit orifice of the inner passage.
- A preferred embodiment of a nebulizer according to the present invention is shown in the enclosed Figures, among which:
-
Figure 1 represents an exploded view of an embodiment of a nebulizer according to the present invention, -
Figure 2 is an enlarged view of the cover ofFigure 1 , -
Figure 3 is a longitudinal sectional view of the nebulizer ofFigure 1 , -
Figure 4 is an elevation view of the reservoir of the nebulizer ofFigure 1 , -
Figures 5a-5c illustrate the assembling of the reservoir to the nebulizer body of the nebulizer ofFigure 1 , -
Figures 6a-6c illustrate the assembling of the cover to the nebulizer body of the assembly ofFigure 5c , and -
Figures 7a-7b illustrate the connecting of a respiratory interface, e.g. a mouthpiece, to the nebulizer body of the assembly ofFigures 6c . -
Figure 1 represents an exploded view an embodiment of a nebulizer 1 according to the present invention designed for aerosolizing a liquid, such as a drug useable in aerosoltherapy, which comprises: - a
reservoir 3 forming the lower part of the nebulizer 1, and which is designed for receiving and containing a liquid to be aerosolized, in particular a drug-containing solution, - a
nebulizer body 2 comprising an aerosol-generatingsystem 4, 23, 24 for generating an aerosol, i.e. a mist, and anebulization chamber 5 for containing the aerosol, i.e. the mist, generated by the aerosol-generatingsystem 4, 23, 24, - a
cover 7 comprising avalve system - a
respiratory interface 6 for delivering the drug-containing mist to a patient. - As shown in
Figures 1 ,3 and4 , thereservoir 3 comprises aliquid tank 14, also called liquid vessel or compartment, for receiving the liquid to be aerosolized, and further aninner conduit 18, as shown inFig. 3 , arranged so as to project axially and upwardly into theliquid tank 14 of thereservoir 3. Preferably, thetank 14 of thereservoir 3 has a "cup-like" shape. - Furthermore, the
inner conduit 18 is arranged at the center of theliquid tank 14 of thereservoir 3. The role of theinner conduit 18 is to convey a pressurized gas delivered by a gas source (not shown), such as compressed air, fluidly connected to theupstream end 18a of theinner conduit 18. The gas flow travels into the lumen or inner passage 18c of theinner conduit 18 and is delivered by thedownstream end 18b of theinner conduit 18 for creating the mist or aerosol as explained below. - Preferably, the
reservoir 3 is detachably attached to thenebulizer body 2, for instance they are snap-fitted or threadedly-coupled together, or similarly adapted for repeated attachment/detachment. - In the embodiment of
Figure 1 and as shown inFigures 5a-5c , when thereservoir 3 is assembled by means of a snap-fit connection or similar (19 inFigure 3 ) to thenebulizer body 2, one (or several) picot or pin element(s) 20 arranged on the outer surface of thereservoir 3 fit(s) into, i.e. is (are) received into, one (or several) lodging(s) 21 arranged in the peripheral wall of thenebulizer body 2, i.e. bore(s) traversing the peripheral wall of thenebulizer body 2. This ensures a good positioning of thereservoir 3 with respect to thenebulizer body 2 as well as an improved fixation of those parts together, when they are snap-fitted or the like. - Further, the
nebulizer body 2 forming the main part of the nebulizer 1 comprises atop opening 10 that is closed by anupper cover 7 forming the "top" or "roof" of thenebulizer body 2 as shown inFigure 1 . - More precisely, the
nebulizer body 2 comprises, as shown inFigure 3 : - an aerosol-generating system 4 for generating an aerosol, i.e. a mist,
- a
nebulization chamber 5 for containing the aerosol, i.e. the mist, generated by the aerosol-generating system 4, and - an axially-arranged
inner conduit 13 comprising an air inlet at itsupper end 13a, an air outlet 13b at its lower end 13b and an internal passage 13c arranged in-between for conveying ambient air from the air inlet towards the air outlet. - Preferably, at least a part of the
nebulization chamber 5 is positioned between theperipheral wall 2a of thenebulizer body 2 and the axially-arrangedinner conduit 13, and further located above theliquid tank 14. - As shown in
Figure 3 , when thereservoir 3 is assembled to thenebulizer body 2, thedownstream end 18b of theinner conduit 18 is inserted into the internal passage 13c of the lower end 13b of the axially-arrangedinner conduit 13, i.e. thedownstream end 18b of theinner conduit 18 passes through the air outlet 13b of the the axially-arrangedinner conduit 13 of thenebulizer body 2. - In other words, the lower end 13b of the axially-arranged
inner conduit 13 of thenebulizer body 2 forms a sleeve around thedownstream end 18b of theinner conduit 18 of thereservoir 3. - The lower end 13b of the axially-arranged
inner conduit 13 of thenebulizer body 2 further projects into theliquid tank 14 of thereservoir 3 and terminates close to the bottom 14a of theliquid tank 14 as shown inFigure 3 , preferably at a distance of less than about 2 mm. - In the aim of allowing a circulation of liquid between them, a
spacing 22 is kept, on the one hand, between the extremity of the lower end 13b of the axially-arrangedinner conduit 13 and the bottom 14a of theliquid tank 14 and, on the second hand, between the inner wall of the lower end 13b of the axially-arrangedinner conduit 13 and the outer wall of thedownstream end 18b of theinner conduit 18 of thereservoir 3. - Preferably, the distance between the inner wall of the lower end 13b of the axially-arranged
inner conduit 13 and the outer wall of thedownstream end 18b of theinner conduit 18 of thereservoir 3 is of less than about 1 mm. - Indeed, for generating the aerosol mist, the liquid contained into the
tank 14 of thereservoir 3 should be able to circulate in saidspacing 22 for reaching the aerosol-generatingsystem 4, 23,24, as explained below. - The aerosol-generating
system 4, 23, 24 is arranged in the lumen 13c of theinner conduit 13 of thenebulizer body 2 and comprises, as shown inFigure 3 : - a
nozzle element 23 with a small orifice 24 forming a flow restriction, for instance a restriction orifice 24 having a diameter or dimensions of between about 1 mm to 5 mm. The orifice 24 can have a circular section, an ellipse section or any other suitable shape. Preferably, thenozzle element 23 is axially arranged into lumen 13c. - and a deflector element 4 facing the small orifice 24 of the
nozzle element 23, such as a little wall, blade, pin or similar that is arranged into lumen 13c, preferably radially-positioned into lumen 13c. - Such an aerosol-generating
system 4, 23, 24 can generate the aerosol mist thanks to a Venturi effect. This principle is well-known in the art. In few words, pressurized air is conveyed and delivered by by theinner conduit 18 of thereservoir 3, at a high speed and a constant flowrate. This creates a suction effect that moves the liquid solution out of thetank 14. The liquid solution travels in thespacing 22, i.e. it is upwardly pulled by the suction effect, and is then delivered by the small orifice 24 of thenozzle element 23 toward the deflector element 4. When the liquid enters into contact with the deflector element 4, a mist of liquid droplets is created by the impact of the liquid on the deflector element 4. The smaller droplets create the desired aerosol mist that is recovered into thenebulization chamber 5, whereas the larger and/or heavier droplets return to theliquid tank 14. The aerosol mist can thereafter be inhaled by the patient via arespiratory interface 6. - Indeed, a
respiratory interface 6, also called "patient interface", is fixed to thenebulizer body 2 and is in fluid communication with thenebulization chamber 5 so that the aerosol created in thenebulization chamber 5 can be delivered to a patient by saidrespiratory interface 6 as illustrated inFigure 3 . - As shown in
Figure 1 , therespiratory interface 6 can be amouthpiece 30, or a mouth or facialrespiratory mask 31, 32, or similar. The choice of the mostsuitable interface 6 depends on the type of medication to be taken and on the type of patients i.e. the facial mask is suitable for non collaborative pediatric patients, while the mouthpiece and mouth mask are better for adults. - In the embodiment of
Figures 1 ,3 and7a-7b , therespiratory interface 6 is amouthpiece 30 with aninner passage 15, that is designed so that the patient takes it into his/her mouth for inhaling the drug-containing mist. Actually, themouthpiece 30 is traversed by aninner passage 15 that is in fluid communication with thenebulization chamber 5. - Generally speaking, the
respiratory interface 6 comprises a proximal end 6a connected to thenebulizer body 2 and adistal end 6b that is free and which comprises theexit orifice 16 of theinner passage 15. - In the case of a
mouthpiece 30, thedistal end 6b is further designed so as to form a "beak-shape nozzle" that the patient takes in mouth, whereas in the case of a mouth or facialrespiratory mask 31, 32, thedistal end 6b is further designed so as to form an enclosure that is large enough for receiving at least a part of the patient's nose or nose and mouth, through theexit orifice 16. -
Figures 7a-7b show the attachment of amouthpiece 30 to thenebulizer body 2 of the nebulizer 1 ofFigure 1 . However, attaching of a mouth or facialrespiratory mask 31, 32 can be operated similarly. - Furthermore, the nebulizer 1 further comprises a
detachable cover 7 that forms the "top" of the nebulizer 1 as forming the ceiling of thenebulizer body 2 as illustrated inFigures 1 ,2 and3 . - More precisely, the
cover 7 comprises a lowerperipheral border 11 cooperating with an upperperipheral border 12 delimiting thetop opening 10 of thenebulizer body 2. - For maintaining the
cover 7 detachably attached to thenebulizer body 2, thecover 7 can, for instance, be snap-fitted or similar to thenebulizer body 2 so that the lowerperipheral border 11 of thecover 7 cooperates with the upperperipheral border 12 of thetop opening 10 of thenebulizer body 2. As shown inFigures 1 ,2 and6a-6c , connectingstructures cover 7 and/or thenebulizer body 2 and cooperate together for allowing a tight and integral fixing of thecover 7 to thenebulizer body 2. - Preferably, the
top cover 7 further comprises agrip portion 17 arranged in its outer wall that allows the user, e.g. the patient, to easily remove thecover 7 when attached to thenebulizer body 2, for instance for cleaning thenebulization chamber 5. Thegrip portion 17 can comprise a textured area, i.e. a not-smooth surface, allowing a good grip to the user, e.g. a textured area comprising "ridges" and "valleys". - Furthermore,
similar grip portions 27 are also arranged in theperipheral wall 2a of thenebulizer body 2 for improving the hand grip of the nebulizer 1 by the patient. - All the components of the nebulizer 1, i.e.
cover 7,nebulizer body 2..., are preferably made of plastic material(s), such as PP, PC, ABS, PA, PSU or similar materials, while the masks are made of a soft elastomeric material, such as silicone or the like. - Further, according to the present invention, the
cover 7 comprises avalve system - a one-
way inspiration valve 8 allowing ambient air entering into thenebulization chamber 5 via the axially-arrangedinner conduit 13 of thenebulizer body 2, during the inspiration phases of the patient, and - a one-
way expiration valve 9 allowing gas exiting thenebulization chamber 5, during the expiration phases of the patient, especially expired gases that contains CO2. - Preferably, the one-
way expiration valve 9 is located between the one-way inspiration valve 8 and therespiratory interface 6, when thecover 7 is integrally fixed to thenebulizer body 2. - In other words, the
inspiration valve 8 is located on thecover 7 facing and in fluid communication with the air inlet located at theupper end 13a of the axially-arrangedinner conduit 13, and opens only during inspiration phases of the patient by action of the negative pressure generated by the patient's inspiration, i.e. during inspiration phases. - The
inspiration valve 8 provides an additional flow of ambient air that enters into thenebulization chamber 5 thereby boosting the nebulization (due to a "double" Venturi effect) and significantly increasing the amount of aerosol mist formed into saidnebulizing chamber 5, and further thereby increasing the nebulization rate of the liquid drug, i.e. the solution containing the medication. - In other words, the on-
way inspiration valve 8 allows air to only travel from the outside to the inside of the nebulizer 1, i.e. to enter into thenebulization chamber 5 via the axially-arrangedinner conduit 13. - Further, the
expiration valve 9 is located next to theinspiration valve 8 on thedetachable cover 7, but closer to themouthpiece 6 than theinspiration valve 8. - Said
expiration valve 9 opens by action of the CO2-containing gases exhaled by the patient that create an overpressure (i.e. pressure > 1 bar) in therespiratory interface 6 and at the inlet of thenebulization chamber 5, while the patient is exhaling gases. Said overpressure allows gases to be vented from the nebulizer 1, through theexpiration valve 9, when the patient exhales into therespiratory interface 6. In other words, the on-way expiration valve 9 allows said CO2-containing gas to only travel from the inside to the outside of the nebulizer 1, i.e. to be vented to the atmosphere. - With a nebulizer 1 according to the present invention, the patient does not remove the
respiratory interface 6, such as themouthpiece 30 out of his/her mouth, before starting to expire CO2-containing gases. - In other words, thanks to the nebulizer 1 according to the present invention, the patient can execute his/her aerosoltherapy by both inhaling and exhaling gases through the
respiratory interface 6 and the cover 7 (see arrows inFig. 2 ), the amount of aerosolized drug wasted in the environment is considerably reduced, compared with prior art nebulizers, as the exit of expired gases is controlled by the one-way expiration valve 9, i.e. there is no permanent opening for exhaled air. - Furthermore, it is advantageous to arranged both
valves detachable cover 7, rather than on therespiratory interface 6 because it reduces the number of expiration valves that otherwise would have been necessary for using the nebulizer 1 with different kinds ofrespiratory interfaces 6, i.e.mouthpiece 30, mouth andfacial masks 31, 32, each equipped with an expiration valve. - The nebulizer 1 of the present invention is usable in combination with a source of gas, such as compressed air, for nebulizing a drug-containing solution and thereby obtaining a mist containing droplets of medication having suitable sizes so as to be able to reach the lower airways of the patient that has to inhale said mist in the frame of his/her aerosoltherapy.
Claims (15)
- Nebulizer (1) for aerosolizing a liquid comprising :- a reservoir (3) for receiving a liquid to be aerosolized,- a nebulizer body (2) comprising an aerosol-generating system (4; 23, 24) for generating an aerosol and a nebulization chamber (5) for containing the aerosol,- a cover (7) forming the top of the nebulizer (1),characterized in that the cover (7) comprises :- a one-way inspiration valve (8) allowing air entering into the nebulization chamber (5)- and a one-way expiration valve (9) allowing gas exiting the nebulization chamber (5).
- Nebulizer according to the preceding Claim, characterized in that it further comprises a respiratory interface (6) in fluid communication with the nebulization chamber (5).
- Nebulizer according to any one of the preceding Claims, characterized in that the cover (7) is detachably fixed to the nebulizer body (2).
- Nebulizer according to any one of the preceding Claims, characterized in that the one-way expiration valve (9) is located between the one-way inspiration valve (8) and the respiratory interface (6), when the cover (7) is integrally fixed to the nebulizer body (2).
- Nebulizer according to any one of the preceding Claims, characterized in that the respiratory interface (6) comprises a mouthpiece (30), a mouth mask (31) or a facial mask (32).
- Nebulizer according to any one of the preceding Claims, characterized in that the reservoir (3) comprises a liquid tank (14) for receiving a liquid to be aerosolized,
- Nebulizer according to any one of the preceding Claims, characterized in that the aerosol-generating system (4; 23, 24) comprises a nozzle element (23) comprising an orifice (24) and a deflector element (4) facing the orifice (24) of the nozzle element (23).
- Nebulizer according to any one of the preceding Claims, characterized in that the nebulizer body (2) further comprises an axially-arranged inner conduit (13) comprising a lower end (13b) projecting into the liquid tank (14) of the reservoir (3), preferably the lower end (13b) of the inner conduit (13) terminates close to the bottom (14a) of the liquid tank (14).
- Nebulizer according to any one of the preceding Claims, characterized in that the reservoir (3) further comprises an inner conduit (18) projecting axially and upwardly into the liquid tank (14).
- Nebulizer according to any one of the preceding Claims, characterized in that the axially-arranged inner conduit (13) of the nebulizer body (2) is arranged as a sleeve around a downstream end (18b) of the inner conduit (18) of the reservoir (3).
- Nebulizer according to any one of the preceding Claims, characterized in that the axially-arranged inner conduit (13) of the nebulizer body (2) is spaced from the downstream end (18b) of the inner conduit (18) of the reservoir (3) by a spacing (22).
- Nebulizer according to any one of the preceding Claims, characterized in that the nozzle element (23) and the deflector element (4) of the aerosol-generating system (4; 23, 24) are arranged into the lumen (13c) of the inner conduit (13) of the nebulizer body (2).
- Nebulizer according to any one of the preceding Claims, characterized in that the inspiration valve (8) of the cover (7) is facing and in fluid communication with the air inlet located at the upper end (13a) of the axially-arranged inner conduit (13).
- Nebulizer according to any one of the preceding Claims, characterized in that the nebulization chamber (5) is located above the liquid tank (14).
- Nebulizer according to any one of the preceding Claims, characterized in that the cover (7) comprises a grip portion (17).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17185224.7A EP3441097B1 (en) | 2017-08-08 | 2017-08-08 | Nebulizer for aerosolizing a liquid with a detachable cover including a valve system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17185224.7A EP3441097B1 (en) | 2017-08-08 | 2017-08-08 | Nebulizer for aerosolizing a liquid with a detachable cover including a valve system |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3441097A1 true EP3441097A1 (en) | 2019-02-13 |
EP3441097B1 EP3441097B1 (en) | 2020-09-30 |
Family
ID=59569180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17185224.7A Active EP3441097B1 (en) | 2017-08-08 | 2017-08-08 | Nebulizer for aerosolizing a liquid with a detachable cover including a valve system |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3441097B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3721928A1 (en) | 2019-04-08 | 2020-10-14 | Air Liquide Medical Systems S.R.L. | Nebulizer for aerosolizing a liquid with comfortable nose piece |
EP3912662A1 (en) | 2020-05-19 | 2021-11-24 | Air Liquide Medical Systems S.r.l. | Nebulizer for aerosolizing a liquid comprising a pivotable cap arranged on the top cover including the valve system |
EP4144392A1 (en) | 2021-09-06 | 2023-03-08 | Air Liquide Medical Systems S.R.L. | Aerosoltherapy device comprising a housing made of biopolymeric material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19902847C1 (en) * | 1999-01-20 | 2000-05-18 | Kendall Med Erzeugnisse Gmbh | Nebulizer combines inhalation and outlet valves in single unit, reducing parts count, simplifying and cheapening manufacture and repair, and producing a more compact and elegant unit |
GB2347870A (en) * | 1999-02-22 | 2000-09-20 | Sunrise Medical Hhg Inc | Medical nebuliser |
GB2358356A (en) * | 1999-12-22 | 2001-07-25 | Pari Gmbh | Inhalation atomiser |
WO2003053500A1 (en) * | 2001-12-21 | 2003-07-03 | Trudell Medical International | Nebulizer apparatus and method |
US20110253134A1 (en) * | 2010-04-16 | 2011-10-20 | Atlantean Corp. | Press-type medical aerosol generating device and pressing mechanism for the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE182801T1 (en) * | 1993-05-28 | 1999-08-15 | Pari Gmbh | MOUTHPIECE FOR INHALATION THERAPY DEVICES |
-
2017
- 2017-08-08 EP EP17185224.7A patent/EP3441097B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19902847C1 (en) * | 1999-01-20 | 2000-05-18 | Kendall Med Erzeugnisse Gmbh | Nebulizer combines inhalation and outlet valves in single unit, reducing parts count, simplifying and cheapening manufacture and repair, and producing a more compact and elegant unit |
GB2347870A (en) * | 1999-02-22 | 2000-09-20 | Sunrise Medical Hhg Inc | Medical nebuliser |
GB2358356A (en) * | 1999-12-22 | 2001-07-25 | Pari Gmbh | Inhalation atomiser |
WO2003053500A1 (en) * | 2001-12-21 | 2003-07-03 | Trudell Medical International | Nebulizer apparatus and method |
US20110253134A1 (en) * | 2010-04-16 | 2011-10-20 | Atlantean Corp. | Press-type medical aerosol generating device and pressing mechanism for the same |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3721928A1 (en) | 2019-04-08 | 2020-10-14 | Air Liquide Medical Systems S.R.L. | Nebulizer for aerosolizing a liquid with comfortable nose piece |
EP3912662A1 (en) | 2020-05-19 | 2021-11-24 | Air Liquide Medical Systems S.r.l. | Nebulizer for aerosolizing a liquid comprising a pivotable cap arranged on the top cover including the valve system |
EP4144392A1 (en) | 2021-09-06 | 2023-03-08 | Air Liquide Medical Systems S.R.L. | Aerosoltherapy device comprising a housing made of biopolymeric material |
Also Published As
Publication number | Publication date |
---|---|
EP3441097B1 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11266795B2 (en) | Breath actuated nebulizer | |
JP3802929B2 (en) | Nebulizer respiratory circulator | |
US9126004B2 (en) | Multipurpose therapeutic face mask | |
JP4444877B2 (en) | Nebulizer breathing device | |
US7878194B2 (en) | Inhaler | |
US20160250437A1 (en) | Self-sealing t-piece and valved t-piece | |
US20120318261A1 (en) | Valved Holding Chamber With Whistle for the Administration of Inhalable Drugs | |
JPH05277188A (en) | Drug sprayer with improved aerosol room | |
EP3441097B1 (en) | Nebulizer for aerosolizing a liquid with a detachable cover including a valve system | |
EP2744544B1 (en) | Mouthpiece for delivering nebulized medicament to the airway of a subject | |
US20090050138A1 (en) | Inhaler | |
EP3441098B1 (en) | Nebulizer for aerosoltherapy made of sub-units detachably secured together | |
EP3459577B1 (en) | Nebulizer for aerosolizing a drug solution with an inner flared-out structure limiting the aerosol waste | |
EP3721928B1 (en) | Nebulizer for aerosolizing a liquid with comfortable nose piece | |
JP2009066142A (en) | Inhaler | |
EP3912662A1 (en) | Nebulizer for aerosolizing a liquid comprising a pivotable cap arranged on the top cover including the valve system | |
CN208809240U (en) | A kind of medicine atomizer for saving dose | |
CN114364421A (en) | Aerosol chamber and mouthpiece design for optimizing inhaled dose with neonatal CPAP device | |
JP2008161528A (en) | Inhalation assisting device for nebulizer | |
CN211383235U (en) | Controllable medical atomizer | |
CN2117172U (en) | Breathing mask of ultrasonic atomizer | |
US20230330358A1 (en) | Breath actuated nebulizer | |
CN113476698A (en) | Medical atomizing device | |
KR20240099865A (en) | Chemical liquid cartridge and portable chemical liquid aerosol inhaler | |
WO2021207187A1 (en) | Nebulizer apparatus with antimicrobial exhalation filter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190813 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200318 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AIR LIQUIDE MEDICAL SYSTEMS S.R.L. |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017024472 Country of ref document: DE Ref country code: AT Ref legal event code: REF Ref document number: 1318155 Country of ref document: AT Kind code of ref document: T Effective date: 20201015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201231 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1318155 Country of ref document: AT Kind code of ref document: T Effective date: 20200930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200930 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210201 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210130 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017024472 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
26N | No opposition filed |
Effective date: 20210701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210824 Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210130 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210808 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20220808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220808 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230822 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230828 Year of fee payment: 7 Ref country code: DE Payment date: 20230821 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200930 |